Back to Results
First PageMeta Content
Biology / Microbiology / Gynaecological cancer / Viral diseases / Cervarix / Vaccination / HPV vaccine / Human papillomavirus / Gardasil / Papillomavirus / Medicine / Vaccines


Microsoft Word - IPC HPV 45 Release FINAL _English_ July[removed]
Add to Reading List

Document Date: 2012-05-01 15:27:16

Open Document

File Size: 98,06 KB

Share Result on Facebook

City

Cape Town / Amsterdam / Mississauga / Montreal / /

Company

GlaxoSmithKline Inc. / Merck Frosst Canada / /

Continent

Europe / /

Country

United States / Canada / South Africa / /

Currency

USD / /

/

Event

FDA Phase / /

Facility

National Cancer Institute / Villa LL / University of Alberta / /

IndustryTerm

research-based pharmaceutical / trial protocol / prevention of cervical cancer / /

MedicalCondition

control hepatitis A / cancer / disease / headache / HPV / cervical cancer / cervical infection / Cervical Adenocarcinoma / HPV infection / cervical intraepithelial neoplasia / AS04-adjuvanted cervical cancer / papillomavirus infections / available cervical cancer / CIN / squamous cell cancer / adenocarcinoma / /

MedicalTreatment

vaccination / /

Organization

National Cancer Institute / Congress / World Congress / University of Alberta / /

Person

Tjark Reblin / Barbara Romanowski / Marlo Taylor / /

/

Position

study investigator / Vice-President / Medical and Chief Medical Officer / /

Product

HPV-16/18 AS04-adjuvanted vaccine / HPV-010 / /

ProvinceOrState

Alberta / Maryland / /

PublishedMedium

British Journal of Cancer / /

Region

Asia-Pacific / /

Technology

antibodies / trial protocol / /

URL

www.gsk.ca / www.cervarix.ca / /

SocialTag